XR Securities’s Novavax NVAX Stock Holding History

XR Securities’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,600	Closed	-$212K	–	549
2022 Q3	$212K	Buy	+1,600	New	+$69.3K	0.12%	151

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XR Securities's NVAX Position: Q1 2022 in Review

XR Securities sold out of Novavax (NVAX) in Q1 2022, closing a stake of 4,199 shares — an estimated $601K sold.

XR Securities first reported a position in NVAX in Q3 2020 and held it in 4 quarters. The position peaked at $601K in Q4 2021. 381 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

XR Securities reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
XR Securities sold 4,199 Novavax shares in Q1 2022, an estimated $601K.
XR Securities first reported a position in Novavax in Q3 2020 and held it in 4 quarters.
XR Securities's Novavax position peaked at $601K in Q4 2021.
381 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on XR Securities's 13F filing for Q1 2022, filed 14 Apr 2022.